舒利迭联用富露施治疗稳定期COPD疗效分析

Therapy effects of Seretide and Flumucil union on stable chronic obstructive pulmonary disease

目的探讨联合应用舒利迭(沙美特罗、丙酸氟替卡松复合制剂)和富露施(N-乙酰半胱氨酸泡腾片)对稳定期COPD患者的临床疗效。方法选取稳定期COPD患者38例,分为观察组和对照组。观察组(20例)给予舒利迭1吸,2次/d,富露施0.6 g口服,3次/d;对照组(18例)给予舒利迭1吸,2次/d。疗程均为1个月。观察两组患者治疗后肺功能和生存质量(QOL)评分变化。结果两组患者治疗前、后1 s用力呼气容量(FEV1)、FEV1占预计值%、QOL评分比较均具有统计学差异(P<0.05或P<0.01),治疗后观察组较对照组肺功能和QOL评分改善更为明显(P<0.05)。结论舒利迭与富露施联合应用能够改善稳定期COPD患者的肺功能,并能明显地提高患者的QOL评分。

Objective To study the therapeutic effects of Seretide（Salmeterol and Fluticasone propionate powder for inhalation） and Flumucil（effervescent tablet containing N-acetylcysteine） union on stable chronic obstructive pulmonary disease（COPD）.Methods The research enrolled 38 patients with stable COPD.These patients were randomized into trial group（n=20） and control group（n=18）.The trial group was administered Seretide inhalation twice per day and Flumucil 0.6 g orally three times per day,and the control group was given Seretide alone twice per day.The course of treatment was one months.All the patients were measured in pulmonary function and evaluated in quality of life（QOL）.Results There were obvious changes in FEV1,FEV1% and QOL evaluation between pre-and post-treatment（P0.05,P0.01）.After treatment,the improvements in pulmonary function and QOL were more significant in the trial group than in the control group（P0.05）.Conclusion There are more benefits in treatment of combination of Seretide and Flumucil in pulmonary function and QOL of the patients with stable COPD.